The first RET-targeted anticancer therapy is attempting to receive insurance reimbursement in Korea.

According to industry sources, Lilly Korea has recently submitted a reimbursement application for its ‘Retevmo (selpercatinib) that targets the RET (Rearranged during transfection)-gene fusions. After receiving approval from the Ministry of Food and Drug Safety through the fast track system, the company has been making progress through the approval-reimbursement linkage system.

In 2020, Retevmo was approved as the first treatment option for cancer patients with RET gene alternations in the US after the FDA reviewed the drug through the Accelerated Approval and Priority Review pathway and